Member Profile

Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of neurological and inflammatory diseases. Lumosa Therapeutics is actively engaged in scientific licensing and new drugs development under a “reSEARCH and DEVELOPMENT” model. Through our expertise in translational research, project management, patent management and licensing strategy, we plan for product lifecycle management at the inception of the projects, optimize the development process and maximize the value of our products for out-licensing. Our very capable multi-functional team are experienced in in vitro & in vivo pharmacology, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development. Our project managers and subject matter experts work seamlessly to efficiently identify, select and develop novel drug products with global market potential, and collaborate with our international partners in clinical trials, and product development.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2001 SunTen Phytotech founded.
   2014 Merger of SunTen Phytotech, Cheng Pang Biopharma, and BroadCan Company; name change to Lumosa Therapeutics Co., Ltd. (Lumosa).
   2016 Lumosa Therapeutics is public traded on Taipei Exchange (code: 6535.TWO)
   2017 LT1001 approved by Taiwan FDA.
   2019 LT3001, a novel drug for the treatment of acute ischemic stroke, out-licensed to China
   2020 LT1001 (Naldebain®) approved by Singapore HSA.
   2021 LT1001 (Naldebain®) approved by Thai FDA.
   2022 LT1001 (Naldebain®) approved by Malaysia FDA.